Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

On the basis of strong preclinical rationale, we sought to confirm recommended phase II dose (RP2D) for olaparib, a PARP inhibitor, combined with the AKT inhibitor capivasertib and assess molecular markers of response and resistance. We performed a safety lead-in followed by expansion in endometrial...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research Jg. 27; H. 23; S. 6354
Hauptverfasser:	Westin, Shannon N, Labrie, Marilyne, Litton, Jennifer K, Blucher, Aurora, Fang, Yong, Vellano, Christopher P, Marszalek, Joseph R, Feng, Ningping, Ma, XiaoYan, Creason, Allison, Fellman, Bryan, Yuan, Ying, Lee, Sanghoon, Kim, Tae-Beom, Liu, Jinsong, Chelariu-Raicu, Anca, Chen, Tsun Hsuan, Kabil, Nashwa, Soliman, Pamela T, Frumovitz, Michael, Schmeler, Katheleen M, Jazaeri, Amir, Lu, Karen H, Murthy, Rashmi, Meyer, Larissa A, Sun, Charlotte C, Sood, Anil K, Coleman, Robert L, Mills, Gordon B
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.12.2021
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Female Humans Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Phthalazines Piperazines Pyrimidines Pyrroles Triple Negative Breast Neoplasms - drug therapy
ISSN:	1557-3265, 1557-3265
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!